All News
RA Patients on Biologics and tsDMARDs are still High Risk
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
Read ArticleBest Treatments for Immune Checkpoint Inhibitor-associated Arthritis
A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.
Read ArticleClinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
Read Article
Links:

Links:

Links:

Links:

Links:

Links:

Links:

Links:

Links:

Dr. John Cush RheumNow ( View Tweet)

Links:

Links:

Links:

Links:

Anakinra Phase 2/3 study in severe hosp. COVID-19 pts (5/20-3/21) w/ pneumonia & hyperinflammation (incr levels IL-6, ferritin, CRP, LDH). 179 pt Rx w/ ANA or SOC - d15 need for Mech ventilation was 77% ANAK v 86% SoC (NS; RR 0.90; 0.77-1.04) https://t.co/CFcI1qTsU2 https://t.co/wAj4pHN5Dh
Links:

Links:

Links: